Skip to main content
SpringerLink
Log in

Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men

  • Chapter
  • First Online:
Sex and Gender Factors Affecting Metabolic Homeostasis, Diabetes and Obesity

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1043))

Abstract

Androgens are steroid hormones with pleotropic and diverse biochemical and physiological functions, and androgen deficiency exerts a negative impact on human health. Testosterone (T) either directly or via its transformation into the more potent metabolite 5α-dihydrotestosterone (5α-DHT) or via aromatization into estradiol (E2) modulates important biochemical signaling pathways of human physiology and plays a critical role in the growth and/or maintenance of functions in a host of tissues and organs. T and 5α-DHT play an important role in regulating physiology of the muscle, adipose tissue, liver, bone, and central nervous system, as well as reproductive and sexual functions. Thus, androgen deficiency (also referred to as hypogonadism) is a well-recognized medical condition and if remained untreated will have a negative impact on human health and quality of life.

In this chapter, we have summarized the negative impact of T deficiency (TD) on a host of physiological functions including reduced lean body mass (LBM), increased fat mass (FM), increased insulin resistance (IR), metabolic syndrome (MetS) and adiposity, reduced bone mineral density (BMD), anemia, sexual dysfunction, and reduced quality of life and increased mortality. In addition, we discuss another critical aspect of unrecognized form of androgen deficiency resulting from inhibition of 5α-reductases with drugs, such as finasteride and dutasteride, to block transformation of T into 5α-DHT in the course of treatment of benign prostatic hyperplasia (BPH) and male pattern hair loss, also known as androgenetic alopecia (AGA). The negative impact of drugs that inhibit transformation of T to 5α-DHT by 5α-reductases on metabolic function is manifested in fat accumulation in the liver, which may predispose to nonalcoholic fatty liver disease (NAFLD). Also, inhibition of 5α-DHT formation increases glucose synthesis and reduces glucose disposal potentially contributing to hyperglycemia, IR, and elevated activities of liver function enzymes concomitant with reduction in circulating T levels, worsening erectile dysfunction (ED), and reduced quality of life.

Although we have attempted to summarize the current literature pertaining to this critical topic “androgen deficiency” and its impact on men’s health and quality of life, there remain many gaps in the knowledge regarding the biochemical pathways that are involved in the pathophysiology of androgen deficiency. We wish to clearly state that there are areas of controversies, including whether age-related androgen deficiency (functional hypogonadism) merits treatment and whether T therapy provided real proven benefits. Finally, considerable debate exists with respect to the potential and purported cardiovascular (CV) risks of treating TD with exogenous T. For brevity sake, we will not discuss in detail the benefits of T therapy in men with TD since this topic is comprehensively covered by Dr. F. Saad’s chapter in this book, entitled “Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism).”

We have made a concerted effort to address the controversy of T therapy in men with TD in the discussion. However, we wish to acknowledge that these issues will remain a matter of debate for some time to come. Only with advances in fundamental basic science and clinical research, some of these controversial issues may be laid to rest. Nevertheless, we believe that there is considerable body of credible evidence to suggest that T therapy of men with TD is safe and effective and provides a host of health benefits and therefore merits considerations in men with TD, irrespective of the underlying cause or etiology. An additional aspect of androgen deficiency is the drug-induced reduction in 5α-DHT levels by the use of 5α-reductase inhibitors. We also believe that physicians prescribing 5α-reductase inhibitors (i.e., finasteride or dutasteride) for relief of BPH symptoms or treatment of hair loss should engage their patients in a productive discussion regarding the potential adverse side effects of these medications on their overall health and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

5α-DHT:

5α-Dihydrotestosterone

ALT:

Alanine aminotransferase

AR:

Androgen receptor

ARKO:

Androgen receptor knockout mouse

BMI:

Body mass index

CHF:

Congestive heart failure

CPT1:

Carnitine palmitoyltransferase 1

E2 :

Estradiol

ER:

Estrogen receptor

ERKO:

Knockout mouse for ER

FAS:

Fatty acid synthase

HDL-c:

High-density lipoprotein cholesterol

HFD:

High-fat diet

HgA1c:

Hemoglobin A1c

HOMA-IR:

Homeostatic model of insulin resistance

IR:

Insulin resistance

LDL-c:

Low-density lipoprotein cholesterol

MetS:

Metabolic syndrome

MMP:

Mitochondrial membrane potential

NAFLD:

Nonalcoholic fatty liver disease

NASH:

Nonalcoholic steatohepatitis

P-ACC:

Acetyl coenzyme A carboxylase

P-HMGCR:

3-Hydroxy-3-methyl-glutaryl-CoA reductase

T:

Testosterone

T2DM:

Type 2 diabetes mellitus

TD:

Testosterone deficiency (hypogonadism)

TG:

Triglyceride

TGs:

Triglycerides

UCP2:

Uncoupling protein 2

WC:

Waist circumference

References

  • Ali, A. K., Heran, B. S., & Etminan, M. (2015). Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: A pharmacovigilance study. Pharmacotherapy, 35, 687–695.

    Article  CAS  PubMed  Google Scholar 

  • Allan, C. A., Strauss, B. J., Burger, H. G., Forbes, E. A., & McLachlan, R. I. (2008). Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. The Journal of Clinical Endocrinology and Metabolism, 93, 139–146.

    Article  CAS  PubMed  Google Scholar 

  • Amanatkar, H. R., Chibnall, J. T., Seo, B. W., Manepalli, J. N., & Grossberg, G. T. (2014). Impact of exogenous testosterone on mood: A systematic review and meta-analysis of randomized placebo-controlled trials. Annals of Clinical Psychiatry, 26, 19–32.

    PubMed  Google Scholar 

  • Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004). Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. The Journal of Clinical Endocrinology and Metabolism, 89, 503–510.

    Article  CAS  PubMed  Google Scholar 

  • Amory, J. K., Anawalt, B. D., Matsumoto, A. M., Page, S. T., Bremner, W. J., Wang, C., Swerdloff, R. S., & Clark, R. V. (2008). The effect of 5a-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. The Journal of Urology., 179, 2333–2338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anderson, J. L., May, H. T., Lappé, D. L., Bair, T., Le, V., Carlquist, J. F., & Muhlestein, J. B. (2016). Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. The American Journal of Cardiology, 117, 794–799.

    Article  CAS  PubMed  Google Scholar 

  • Andersson, B., Marin, P., Lissner, L., Vermeulen, A., & Bjorntorp, P. (1994). Testosterone concentrations in women and men with NIDDM. Diabetes Care, 17, 405–411.

    Article  CAS  PubMed  Google Scholar 

  • Andriole, G. L., & Kirby, R. (2003). Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. European Urology, 44, 82–88.

    Article  CAS  PubMed  Google Scholar 

  • Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., Somerville, M. C., Wilson, T. H., Fowler, I. L., & Rittmaster, R. S. (2010). Effect of dutasteride on the risk of prostate cancer. The New England Journal of Medicine, 362, 1192–1202.

    Article  CAS  PubMed  Google Scholar 

  • Antonio, L., Wu, F. C., O'Neill, T. W., Pye, S. R., Carter, E. L., Finn, J. D., Rutter, M. K., Laurent, M. R., Huhtaniemi, I. T., Han, T. S., Lean, M. E., Keevil, B. G., Pendleton, N., Rastrelli, G., Forti, G., Bartfai, G., Casanueva, F. F., Kula, K., Punab, M., Giwercman, A., Claessens, F., Decallonne, B., Vanderschueren, D., & EMAS Study Group. (2015). Associations between sex steroids and the development of metabolic syndrome: A longitudinal study in European men. The Journal of Clinical Endocrinology and Metabolism, 100, 1396–1404.

    Article  CAS  PubMed  Google Scholar 

  • Araujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004). Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. The Journal of Clinical Endocrinology and Metabolism, 89, 5920–5926.

    Article  CAS  PubMed  Google Scholar 

  • Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., Clark, R. V., & McKinlay, J. B. (2007). Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology and Metabolism, 92, 4241–4247.

    Article  CAS  PubMed  Google Scholar 

  • Aub, J. C. (1940). The use of testosterone. The New England Journal of Medicine, 222, 877–881.

    Article  Google Scholar 

  • Aub, J. C., & Kety, S. S. (1943). Recent advances in testosterone therapy. The New England Journal of Medicine, 228, 338–343.

    Article  Google Scholar 

  • Azzolina, B., Ellsworth, K., Andersson, S., Geissler, W., Bull, H. G., & Harris, G. S. (1997). Inhibition of rat alpha-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition. The Journal of Steroid Biochemistry and Molecular Biology, 61, 55–64.

    Article  CAS  PubMed  Google Scholar 

  • Baillargeon, J., Urban, R. J., Kuo, Y. F., Ottenbacher, K. J., Raji, M. A., Du, F., Lin, Y. L., & Goodwin, J. S. (2014). Risk of myocardial infarction in older men receiving testosterone therapy. The Annals of Pharmacotherapy, 48, 1138–1144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baillargeon, J., Urban, R. J., Morgentaler, A., Glueck, C. J., Baillargeon, G., Sharma, G., & Kuo, Y. F. (2015). Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clinic Proceedings, 9, 1038–1045.

    Article  CAS  Google Scholar 

  • Bamberger, C. M., Schulte, H. M., & Chrousos, G. P. (1996). Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Reviews, 17, 245–261.

    Article  CAS  PubMed  Google Scholar 

  • Basaria, S. (2008). Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. Journal of Andrology, 29, 534–539.

    Article  PubMed  Google Scholar 

  • Basaria, S., & Dobs, A. (2001). Hypogonadism and androgen replacement therapy in elderly men. The American Journal of Medicine, 110, 563–572.

    Article  CAS  PubMed  Google Scholar 

  • Basaria, S., & Dobs, A. S. (2007). Testosterone making an entry into the cardiometabolic world. Circulation, 116, 2658–2661.

    Article  PubMed  Google Scholar 

  • Basaria, S., Muller, D., Carducci, M., Egan, J., & Dobs, A. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581–588.

    Article  CAS  PubMed  Google Scholar 

  • Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S. (2010). Adverse events associated with testosterone administration. The New England Journal of Medicine, 363, 109–122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Basaria, S., Jasuja, R., Huang, G., Wharton, W., Pan, H., Pencina, K., Li, Z., Travison, T. G., Bhawan, J., Gonthier, R., Labrie, F., Dury, A. Y., Serra, C., Papazian, A., O’Leary, M., Amr, S., Storer, T. W., Stern, E., & Bhasin, S. (2016). Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. The Journal of Clinical Endocrinology and Metabolism, 101, 4669–4680.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Basurto, L., Zarate, A., Gomez, R., Vargas, C., Saucedo, R., & Galván, R. (2008). Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. The Aging Male, 11, 140–145.

    Article  CAS  PubMed  Google Scholar 

  • Baum, M. J. (1979). A comparison of the effects of methyltrienolone (R 1881) and 5 alpha-dihydrotestosterone on sexual behavior of cas- trated male rats. Hormones and Behavior, 13, 165–174.

    Article  CAS  PubMed  Google Scholar 

  • Bechis, S. K., Otsetov, A. G., Ge, R., & Olumi, A. F. (2014). Personalized medicine for the management of benign prostatic hyperplasia. The Journal of Urology, 192, 16–23.

    Article  PubMed  PubMed Central  Google Scholar 

  • Berry, S. J., & Isaacs, J. T. (1984). Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology, 114, 511–520.

    Article  CAS  PubMed  Google Scholar 

  • Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., Magliano, L., & Storer, T. W. (2005). Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. The Journal of Clinical Endocrinology and Metabolism, 90, 678–688.

    Article  CAS  PubMed  Google Scholar 

  • Bhasin, S., Calof, O. M., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V. M., Gao, W., & Dalton, J. T. (2006). Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature Clinical Practice Endocrinology & Metabolism, 2, 146–159.

    Article  CAS  Google Scholar 

  • Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010). Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 95, 2536–2559.

    Article  CAS  PubMed  Google Scholar 

  • Björntorp, P., & Rosmond, R. (2000). Obesity and cortisol. Nutrition, 16, 924–936.

    Article  PubMed  Google Scholar 

  • Blouin, K., Despres, J. P., Couillard, C., Tremblay, A., Prud’homme, D., Bouchard, C., & Tchernof, A. (2005). Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism, 54, 1034–1040.

    Article  CAS  PubMed  Google Scholar 

  • Blouin, K., Richard, C., Brochu, G., Hould, F. S., Lebel, S., Marceau, S., Biron, S., Luu-The, V., & Tchernof, A. (2006). Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. The Journal of Endocrinology, 191, 637–649.

    Article  CAS  PubMed  Google Scholar 

  • Bolduc, C., Yoshioka, M., & St-Amand, J. (2007). Transcriptomic characterization of the long-term dihydrotestosterone effects in adipose tissue. Obesity (Silver Spring), 15(5), 1107–1132.

    Article  CAS  Google Scholar 

  • Boonen, E., Vervenne, H., Meersseman, P., Andrew, R., Mortier, L., Declercq, P. E., Vanwijngaerden, Y. M., Spriet, I., Wouters, P. J., Vander Perre, S., Langouche, L., Vanhorebeek, I., Walker, B. R., & Van den Berghe, G. (2013). Reduced cortisol metabolism during critical illness. The New England Journal of Medicine, 368, 1477–1488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bradshaw, W. G., Baum, M. J., & Awh, C. C. (1981). Attenuation by a 5 alpha- reductase inhibitor of the activational effect of testosterone propi- onate on penile erections in castrated male rats. Endocrinology, 109, 1047–1051.

    Article  CAS  PubMed  Google Scholar 

  • Budoff, M. J., Ellenberg, S. S., Lewis, C. E., Mohler, E. R., 3rd, Wenger, N. K., Bhasin, S., Barrett-Connor, E., Swerdloff, R. S., Stephens-Shields, A., Cauley, J. A., Crandall, J. P., Cunningham, G. R., Ensrud, K. E., Gill, T. M., Matsumoto, A. M., Molitch, M. E., Nakanishi, R., Nezarat, N., Matsumoto, S., Hou, X., Basaria, S., Diem, S. J., Wang, C., Cifelli, D., & Snyder, P. J. (2017). Testosterone treatment and coronary artery plaque volume in older men with low testosterone. Journal of the American Medical Association, 317(7), 708–716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J. M., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., & Zitzmann, M. (2010). Endocrine aspects of male sexual dysfunctions. The Journal of Sexual Medicine, 7, 1627–1656.

    Article  PubMed  Google Scholar 

  • Buvat, J., Maggi, M., Guay, A., & Torres, L. O. (2013). Testosterone deficiency in men: Systematic review and standard operating procedures for diagnosis and treatment. The Journal of Sexual Medicine, 10, 245–284.

    Article  CAS  PubMed  Google Scholar 

  • Calof, O., Singh, A. B., Lee, M. L., Urban, R. J., Kenny, A. M., Tenover, J. L., & Bhasin, S. (2005). Adverse events associated with testosterone supplementation of older men. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 60, 1451–1457.

    Article  PubMed  Google Scholar 

  • Camacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Tajar, A., Bartfai, G., Boonen, S., Casanueva, F. F., Forti, G., Giwercman, A., Han, T. S., Kula, K., Keevil, B., Lean, M. E., Pendleton, N., Punab, M., Vanderschueren, D., Wu, F. C., & EMAS Group. (2013). Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European Male Ageing Study. European Journal of Endocrinology, 168, 445–455.

    Article  CAS  PubMed  Google Scholar 

  • Carruthers, M., Trinick, T. R., Jankowska, E., & Traish, A. M. (2008). Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovascular Diabetology, 7, 30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Caruso, D., Abbiati, F., Giatti, S., Romano, S., Fusco, L., Cavaletti, G., & Melcangi, R. C. (2015). Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. The Journal of Steroid Biochemistry and Molecular Biology, 146, 74–79.

    Article  CAS  PubMed  Google Scholar 

  • Cauci, S., Chiriacò, G., Cecchin, E., Toffoli, G., Xodo, S., Stinco, G., & Trombetta, C. (2017). Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sexual Medicine, 5, e61–e71.

    Article  PubMed  Google Scholar 

  • Chazenbalk, G., Singh, P., Irge, D., Shah, A., Abbott, D. H., & Dumesic, D. A. (2013). Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids, 78, 920–926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cheetham, T. C., An, J., Jacobsen, S. J., Niu, F., Sidney, S., Quesenberry, C. P., & VanDenEeden, S. K. (2017). Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Internal Medicine, 177, 491–499.

    Article  PubMed  Google Scholar 

  • Chen, R. Y. T., Wittest, G. A., & Andreson, G. R. (2006). Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes, Obesity & Metabolism, 8, 429–435.

    Article  CAS  Google Scholar 

  • Chi, B. H., & Kim, S. C. (2011). Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean Journal of Urology, 52, 632–636.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chiriacò, G., Cauci, S., Mazzon, G., & Trombetta, C. (2016). An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology, 4, 245–250.

    Article  CAS  PubMed  Google Scholar 

  • Choi, S. K., Han, S. W., Kim, D. H., & de Lignieres, B. (1993). Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. The Journal of Urology, 150(2 Pt 2), 657–660.

    Article  CAS  PubMed  Google Scholar 

  • Choi, G. S., Kim, J. H., Oh, S. Y., Park, J. M., Hong, J. S., Lee, Y. S., & Lee, W. S. (2016). Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Annals of Dermatology, 28, 444–450.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cohen, P. G. (1999). The hypogonadal-obesity cycle: Role of aromatase in modulating the testosterone-estradiol shunt – a major factor in the genesis of morbid obesity. Medical Hypotheses, 52, 49–51.

    Article  CAS  PubMed  Google Scholar 

  • Colangelo, L. A., Ouyang, P., Liu, K., Kopp, P., Golden, S. H., Dobs, A. S., Szklo, M., Vaidya, D., Cushman, M., & Gapstur, S. M. (2009). Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: Multi-ethnic study of atherosclerosis. Diabetes Care, 32, 1049–1051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Corona, G., Mannucci, E., Mansani, R., Petrone, L., Bartolini, M., Giommi, R., Forti, G., & Maggi, M. (2004). Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. European Urology, 46, 222–228.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Mannucci, E., Petrone, L., Ricca, V., Balercia, G., Mansani, R., Chiarini, V., Giommi, R., Forti, G., & Maggi, M. (2006). Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. International Journal of Impotence Research, 18, 190–197.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Mannucci, E., Petrone, L., Balercia, G., Paggi, F., Fisher, A. D., Lotti, F., Chiarini, V., Fedele, D., Forti, G., & Maggi, M. (2007). NCEP-ATPIII defined metabolic syndrome, type 2 diabetes mellitus, and prevalnce of hypogonadism in male patients with sexual dysfunction. The Journal of Sexual Medicine, 4, 1038–1045.

    Article  PubMed  Google Scholar 

  • Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011a). Testosterone and metabolic syndrome: A meta-analysis study. The Journal of Sexual Medicine, 8, 272–283.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Monami, M., Rastrelli, G., Aversa, A., Sforza, A., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011b). Type 2 diabetes mellitus and testosterone: A meta-analysis study. International Journal of Andrology, 34, 528–540.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: A systematic review and meta-analysis. European Journal of Endocrinology, 168, 829–843.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Isidori, A. M., Buvat, J., Aversa, A., Rastrelli, G., Hackett, G., Rochira, V., Sforza, A., Lenzi, A., Mannucci, E., & Maggi, M. (2014). Testosterone supplementation and sexual function: A meta-analysis study. The Journal of Sexual Medicine, 11, 1577–1592.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016). Therapy of endocrine disease: Testosterone supplementation and body composition: Results from a meta-analysis study. European Journal of Endocrinology, 174, R99–116.

    Article  CAS  PubMed  Google Scholar 

  • Corona, G., Tirabassi, G., Santi, D., Maseroli, E., Gacci, M., Dicuio, M., Sforza, A., Mannucci, E., & Maggi, M. (2017). Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: A comprehensive review and meta-analysis. Andrology, 5, 671–678.

    Article  CAS  PubMed  Google Scholar 

  • Couillard, C., Gagnon, J., Bergeron, J., Leon, A. S., Rao, D. C., Skinner, J. S., Wilmore, J. H., Desprs, J. P., & Bouchard, C. (2000). Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: The HERITAGE Family Study. The Journal of Clinical Endocrinology and Metabolism, 85, 1026–1031.

    CAS  PubMed  Google Scholar 

  • Cunningham, G. R., Stephens-Shields, A. J., Rosen, R. C., Wang, C., Bhasin, S., Matsumoto, A. M., Parsons, J. K., Gill, T. M., Molitch, M. E., Farrar, J. T., Cella, D., Barrett-Connor, E., Cauley, J. A., Cifelli, D., Crandall, J. P., Ensrud, K. E., Gallagher, L., Zeldow, B., Lewis, C. E., Pahor, M., Swerdloff, R. S., Hou, X., Anton, S., Basaria, S., Diem, S. J., Tabatabaie, V., Ellenberg, S. S., & Snyder, P. J. (2016). Testosterone treatment and sexual function in older men with low testosterone levels. The Journal of Clinical Endocrinology and Metabolism, 101, 3096–3104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Lignieres, B. (1993). Transdermal dihydrotestosterone treatment of ‘andropause’. Annals of Medicine, 25, 235–241.

    Article  PubMed  Google Scholar 

  • Debruyne, F., Barkin, J., van Erps, P., Reis, M., Tammela, T. L., & Roehrborn, C. (2004). ARIA3001, ARIA3002 and ARIB3003 study investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. European Urology, 46, 488–494.

    Article  CAS  PubMed  Google Scholar 

  • Debruyne, F. M., Behre, H. M., Roehrborn, C. G., Maggi, M., Wu, F. C., Schröder, F. H., Jones, T. H., Porst, H., Hackett, G., Wheaton, O. A., Martin-Morales, A., Meuleman, E., Cunningham, G. R., Divan, H. A., & Rosen, R. C. (2017). RHYME Investigators. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: Prostate health outcomes in the Registry of Hypogonadism in Men. BJU International, 119, 216–224.

    Article  CAS  PubMed  Google Scholar 

  • DeRijk, R., Schaaf, M., & de Kloet, E. (2002). Glucocorticoid receptor variants: Clinical implications. The Journal of Steroid Biochemistry and Molecular Biology, 81, 103–122.

    Article  CAS  PubMed  Google Scholar 

  • Derweesh, I. H., DiBlasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., Kitabchit, A. E., & Wake, R. N. (2007). Risk of new-onset diabetes mellitus and worsening glycemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International, 100, 1060–1065.

    PubMed  Google Scholar 

  • Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004). Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 89, 5462–5468.

    Article  CAS  PubMed  Google Scholar 

  • Dhindsa, S., Miller, M. G., McWhirter, C. L., et al. (2010). Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care, 33, 1186–1192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Di Dalmazi, G., Pagotto, U., Pasquali, R., & Vicennati, V. (2012). Glucocorticoids and type 2 diabetes: From physiology to pathology. Journal of Nutrition and Metabolism, 2012, 1–9.

    Article  CAS  Google Scholar 

  • Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006). Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. Journal of the American Medical Association, 295, 1288–1299.

    Article  CAS  PubMed  Google Scholar 

  • Dobs, A. S., Bachorik, P. S., Arver, S., Meikle, A. W., Sanders, S. W., Caramelli, K. E., & Mazer, N. A. (2001). Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. The Journal of Clinical Endocrinology and Metabolism, 86, 1026–1033.

    CAS  PubMed  Google Scholar 

  • Dockery, F., Bulpitt, C. J., Agarwal, S., Donaldson, M., & Rajkumar, C. (2003). Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science, 104, 195–201.

    Article  CAS  PubMed  Google Scholar 

  • Dowman, J. K., Hopkins, L. J., Reynolds, G. M., Armstrong, M. J., Nasiri, M., Nikolaou, N., van Houten, E. L., Visser, J. A., Morgan, S. A., Lavery, G. G., Oprescu, A., Hübscher, S. G., Newsome, P. N., & Tomlinson, J. W. (2013). Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology, 154, 4536–4547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dubois, V., Laurent, M. R., Jardi, F., Antonio, L., Lemaire, K., Goyvaerts, L., Deldicque, L., Carmeliet, G., Decallonne, B., Vanderschueren, D., & Claessens, F. (2016). Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice. Endocrinology, 157, 648–665.

    Article  CAS  PubMed  Google Scholar 

  • Edwards, J. P., West, S. J., Pooley, C. L., Marschke, K. B., Farmer, L. J., & Jones, T. K. (1998). New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorganic & Medicinal Chemistry Letters, 8, 745–750.

    Article  CAS  Google Scholar 

  • Eisenberg, M. L., Li, S., Herder, D., Lamb, D. J., & Lipshultz, L. I. (2015). Testosterone therapy and mortality risk. International Journal of Impotence Research, 27, 46–48.

    Article  CAS  PubMed  Google Scholar 

  • Emmelot-Vonk, M. H., Verhaar, H. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M., Bosch, J. L., Grobbee, D. E., & van der Schouw, Y. T. (2008). Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: A randomized controlled trial. Journal of the American Medical Association, 299, 39–52.

    CAS  PubMed  Google Scholar 

  • Erdemir, F., Harbin, A., & Hellstrom, W. J. (2008). 5-alpha reductase inhibitors and erectile dysfunction: The connection. The Journal of Sexual Medicine, 5, 2917–2924.

    Article  PubMed  Google Scholar 

  • Etminan, M., Skeldon, S. C., Goldenberg, S. L., Carleton, B., & Brophy, J. M. (2015). Testosterone therapy and risk of myocardial infarction: A pharmacoepidemiologic study. Pharmacotherapy, 35, 72–78.

    Article  CAS  PubMed  Google Scholar 

  • Ferris, H. A., & Kahn, C. R. (2012). New mechanisms of glucocorticoid-induced insulin resistance: Make no bones about it. The Journal of Clinical Investigation, 122, 3854–3857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., Jr., & Hoover, R. N. (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 9, e85805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fukui, M., Soh, J., Tanaka, M., Kitagawa, Y., Hasegawa, G., Yoshikawa, T., Miki, T., & Nakamura, N. (2007). Low serum testosterone concentration in middle-aged men with type 2 diabetes. Endocrine Journal, 54, 871–877.

    Article  CAS  PubMed  Google Scholar 

  • Fukui, M., Tanaka, M., Hasegawa, G., Yoshikawa, T., & Nakamura, N. (2008). Association between serum bioavailable testosterone concentration and the ratio of glycated albumin to glycated hemoglobin in men with type 2 diabetes. Diabetes Care, 31, 397–401.

    Article  CAS  PubMed  Google Scholar 

  • Fwu, C.-W., Eggers, P., Kaplan, S. A., Kirkali, Z., Lee, J. Y., & Kusek, J. W. (2013). Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. The Journal of Urology, 190, 187–193.

    Article  CAS  PubMed  Google Scholar 

  • Fwu, C. W., Eggers, P. W., Kirkali, Z., McVary, K. T., Burrows, P. K., & Kusek, J. W. (2014). Change in sexual function in men with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) associated with long-term treatment with doxazosin, finasteride, and combined therapy. The Journal of Urology, 191, 1828–1834.

    Article  CAS  PubMed  Google Scholar 

  • Ganzer, C. A., Jacobs, A. R., & Iqbal, F. (2015). Persistent sexual, emotional, and cognitive impairment post-finasteride: A survey of men reporting symptoms. American Journal of Men’s Health, 9, 222–228.

    Article  PubMed  Google Scholar 

  • Giatti, S., Rigolio, R., Romano, S., Mitro, N., Viviani, B., Cavaletti, G., Caruso, D., Garcia-Segura, L. M., & Melcangi, R. C. (2015). Dihydrotestosterone as protective agent in chronic experimental autoimmune encephalomyelitis. Neuroendocrinology, 101, 296–308.

    Article  CAS  PubMed  Google Scholar 

  • Gray, G. D., Smith, E. R., & Davidson, J. M. (1980). Hormonal regulation of penile erection in castrated male rats. Physiology & Behavior, 24, 463–468.

    Article  CAS  Google Scholar 

  • Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., Macisaac, R. J., Clark, S., Zajac, J. D., & Jerums, G. (2008). Low testosterone levels are common and associated with insulin resistance in men with diabetes. The Journal of Clinical Endocrinology and Metabolism, 93, 1834–1840.

    Article  CAS  PubMed  Google Scholar 

  • Guo, M., Heran, B., Flannigan, R., Kezouh, A., & Etminan, M. (2016). Persistent sexual dysfunction with finasteride 1 mg taken for hair loss. Pharmacotherapy, 36, 1180–1184.

    Article  CAS  PubMed  Google Scholar 

  • Gupta, A. K., & Charrette, A. (2014). The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: A network meta-analysis and benefit-risk assessment of finasteride and dutasteride. Journal of Dermatological Treatment, 25, 156–161.

    Article  CAS  PubMed  Google Scholar 

  • Gupta, V., Bhasin, S., Guo, W., Singh, R., Miki, R., Chauhan, P., Choong, K., Tchkonia, T., Lebrasseur, N. K., Flanagan, J. N., Hamilton, J. A., Viereck, J. C., Narula, N. S., Kirkland, J. L., & Jasuja, R. (2008). Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Molecular and Cellular Endocrinology, 296, 32–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gur, S., Kadowitz, P. J., & Hellstrom, W. J. (2013). Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opinion on Drug Safety, 12, 81–90.

    Article  CAS  PubMed  Google Scholar 

  • Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013). Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. The Journal of Sexual Medicine, 10, 1612–1627.

    Article  CAS  PubMed  Google Scholar 

  • Hackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & BLAST Study Group. (2014). Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST study. The Journal of Sexual Medicine, 11, 840–856.

    Article  CAS  PubMed  Google Scholar 

  • Hackett, G., Cole, N., Saghir, A., Jones, P., Strange, R. C., & Ramachandran, S. (2016a). Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: Results from a 30-week randomized placebo-controlled study. BJU International, 118, 804–813.

    Article  CAS  PubMed  Google Scholar 

  • Hackett, G., Heald, A. H., Sinclair, A., Jones, P. W., Strange, R. C., & Ramachandran, S. (2016b). Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: Retrospective consideration of the impact of PDE5 inhibitors and statins. International Journal of Clinical Practice, 70, 244–253.

    Article  CAS  PubMed  Google Scholar 

  • Haffner, S. M., Shaten, J., Stern, M. P., Smith, G. D., & Kuller, L. (1996). Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT research group. Multiple risk factor intervention trial. American Journal of Epidemiology, 143, 889–897.

    Article  CAS  PubMed  Google Scholar 

  • Haffner, S. M., Miettinen, H., Karhapa, P., Mykkanen, L., & Laakso, M. (1997). Leptin concentrations, sex hormones, and cortisol in nondiabetic men. The Journal of Clinical Endocrinology and Metabolism, 82, 1807–1809.

    CAS  PubMed  Google Scholar 

  • Haider, A., Yassin, A., Saad, F., & Shabsigh, R. (2007). Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. The Aging Male, 10, 189–196.

    Article  CAS  Google Scholar 

  • Haider, A., Saad, F., Doros, G., & Gooren, L. (2014a). Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obesity Research and Clinical Practice, 8, e339–e349.

    Article  PubMed  Google Scholar 

  • Haider, A., Yassin, A., Doros, G., & Saad, F. (2014b). Effects of long-term testosterone therapy on patients with “diabesity”: Results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International Journal of Endocrinology, 2014, 683515.

    PubMed  PubMed Central  Google Scholar 

  • Haider, K. S., Haider, A., Doros, G., & Traish, A. (2017). Long-term testosterone therapy improves urinary and sexual function and quality of life in men with hypogonadism: Results from a propensity matched subgroup of a controlled registry study. The Journal of Urology, pii: S0022-5347(17), 77145–77145.

    Google Scholar 

  • Hamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., & Grossmann, M. (2011). Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology, 74, 377–383.

    Article  CAS  PubMed  Google Scholar 

  • Hanske, J. N. V. L., Gild, P., Cole, A., Jiang, W., Lipsitz, S., Kathrins, M., Learn, P., Menon, M., Noldus, J., Sun, M., & Trinh, Q.-D. (2017). Adverse effects of testosterone replacement therapy for men, a matched cohort study. European Urology Supplements, 16(3), e448–e450.

    Article  Google Scholar 

  • Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., Blackman, M. R., & Baltimore Longitudinal Study of Aging. (2001). Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology and Metabolism, 86, 724–731.

    Article  CAS  PubMed  Google Scholar 

  • Hart, B. L. (1973). Effects of testosterone propionate and dihydrotestoster- one on penile morphology and sexual reflexes of spinal male rats. Hormones and Behavior, 4, 239–246.

    Article  CAS  PubMed  Google Scholar 

  • Hart, B. L. (1979). Activation of sexual reflexes of male rats by dihydrotes- tosterone but not estrogen. Physiology & Behavior, 23, 107–109.

    Article  CAS  Google Scholar 

  • Hazlehurst, J. M., Oprescu, A. I., Nikolaou, N., Di Guida, R., Grinbergs, A. E., Davies, N. P., Flintham, R. B., Armstrong, M. J., Taylor, A. E., Hughes, B. A., Yu, J., Hodson, L., Dunn, W. B., & Tomlinson, J. W. (2016). Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. The Journal of Clinical Endocrinology and Metabolism, 101, 103–113.

    Article  CAS  PubMed  Google Scholar 

  • Hellman, L., Nakada, F., Zumoff, B., Fukushima, D., Bradlow, H. L., & Gallagher, T. F. (1971). Renal capture and oxidation of cortisol in man. The Journal of Clinical Endocrinology and Metabolism, 33, 52–62.

    Article  CAS  PubMed  Google Scholar 

  • Hofstra, J., Loves, S., van Wageningen, B., Ruinemans-Koerts, J., Jansen, I., & de Boer, H. (2008). High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. The Netherlands Journal of Medicine, 66, 103–109.

    CAS  PubMed  Google Scholar 

  • Idan, A., Griffiths, K. A., Harwood, D. T., Seibel, M. J., Turner, L., Conway, A. J., & Handelsman, D. J. (2010). Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: A randomized, placebo-controlled trial. Annals of Internal Medicine, 153, 621–632.

    Article  PubMed  Google Scholar 

  • Inaba, M., Otani, Y., Nishimura, K., Takaha, N., Okuyama, A., Koga, M., & Kasayama, S. (2005). Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism, 54, 55–59.

    Article  CAS  PubMed  Google Scholar 

  • Irwig, M. S. (2012a). Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. The Journal of Clinical Psychiatry, 73, 1220–1223.

    Article  CAS  PubMed  Google Scholar 

  • Irwig, M. S. (2012b). Persistent sexual side effects of finasteride: Could they be permanent? The Journal of Sexual Medicine, 9, 2927–2932.

    Article  PubMed  Google Scholar 

  • Irwig, M. S. (2013). Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report. Alcoholism, Clinical and Experimental Research, 37, 1823–1826.

    Article  CAS  PubMed  Google Scholar 

  • Irwig, M. S. (2014). Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatology, 150, 1361–1363.

    Article  PubMed  Google Scholar 

  • Irwig, M. S., & Kolukula, S. (2011). Persistent sexual side effects of finasteride for male pattern hair loss. The Journal of Sexual Medicine, 8, 1747–1753.

    Article  PubMed  Google Scholar 

  • Isidori, A. M., Strollo, F., More, M., Caprio, M., Aversa, A., Moretti, C., Frajese, G., Riondino, G., & Fabbri, A. (2000). Leptin and aging: Correlation with endocrine changes in male and female healthy adult populations of different body weights. The Journal of Clinical Endocrinology and Metabolism, 85, 1954–1962.

    Article  CAS  PubMed  Google Scholar 

  • Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005). Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clinical Endocrinology, 63, 280–293.

    Article  CAS  PubMed  Google Scholar 

  • Isidori, A. M., Buvat, J., Corona, G., Goldstein, I., Jannini, E. A., Lenzi, A., Porst, H., Salonia, A., Traish, A. M., & Maggi, M. (2014). A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment-a systematic review. European Urology, 65, 99–112.

    Article  CAS  PubMed  Google Scholar 

  • Jockenhövel, F., Minnemann, T., Schubert, M., Freude, S., Hübler, D., Schumann, C., Christoph, A., & Ernst, M. (2009). Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. European Journal of Endocrinology, 160, 815–819.

    Article  CAS  PubMed  Google Scholar 

  • Jones, T. H. (2010). Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. Journal of Diabetes, 2, 146–156.

    Article  CAS  PubMed  Google Scholar 

  • Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., Channer, K. S., & TIMES2 Investigators. (2011). Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care, 34, 828–837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Joyce, K. E., Biggs, M. L., Djoussé, L., Ix, J. H., Kizer, J. R., Siscovick, D. S., Shores, M. M., Matsumoto, A. M., & Mukamal, K. J. (2017). Testosterone, dihydrotestosterone, sex hormone binding globulin and incident diabetes among older men: The Cardiovascular Health Study. The Journal of Clinical Endocrinology and Metabolism, 102, 33–39.

    PubMed  Google Scholar 

  • Kaplan, S. A., Chung, D. E., Lee, R. K., Scofield, S., & Te, A. E. (2012). A 5-year retrospective analysis of 5alpha-reductase inhibitors in men with benign prostatic hyperplasia: Finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. International Journal of Clinical Practice, 66, 1052–1055.

    Article  CAS  PubMed  Google Scholar 

  • Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006). Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 154, 899–906.

    Article  CAS  PubMed  Google Scholar 

  • Kapoor, D., Aldred, H., Clark, S., Channer, K., & Jones, T. (2007). Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care, 30, 911–917.

    Article  CAS  PubMed  Google Scholar 

  • Keating, N. L., O’Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448–4456.

    Article  CAS  PubMed  Google Scholar 

  • Keating, N. L., O’Malley, A., Freedland, S. J., & Smith, M. R. (2012). Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. Journal of the National Cancer Institute, 104, 1518–1523.

    Article  PubMed  Google Scholar 

  • Keating, N. L., Liu, P. H., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2014). Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. European Urology, 65(4), 816–824.

    Article  CAS  PubMed  Google Scholar 

  • Kelly, D. M., & Jones, T. H. (2013a). Testosterone: A metabolic hormone in health and disease. The Journal of Endocrinology, 217, R25–R45.

    Article  CAS  PubMed  Google Scholar 

  • Kelly, D. M., & Jones, T. H. (2013b). Testosterone: A vascular hormone in health and disease. The Journal of Endocrinology, 217, R47–R71.

    Article  CAS  PubMed  Google Scholar 

  • Kelly, D. M., & Jones, T. H. (2014). Testosterone and cardiovascular risk in men. Frontiers of Hormone Research, 43, 1–20.

    PubMed  Google Scholar 

  • Kelly, D. M., & Jones, T. H. (2015). Testosterone and obesity. Obesity Reviews, 16, 581–606.

    Article  CAS  PubMed  Google Scholar 

  • Kelly, D. M., Nettleship, J. E., Akhtar, S., Muraleedharan, V., Sellers, D. J., Brooke, J. C., McLaren, D. S., Channer, K. S., & Jones, T. H. (2014). Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sciences, 109, 95–103.

    Article  CAS  PubMed  Google Scholar 

  • Kelly, D. M., Akhtar, S., Sellers, D. J., Muraleedharan, V., Channer, K. S., & Jones, T. H. (2016). Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse. Endocrine, 54, 504–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kenny, A. M., Kleppinger, A., Annis, K., Rathier, M., Browner, B., Judge, J. O., & McGee, D. (2010). Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. Journal of the American Geriatrics Society, 58, 1134–1143.

    Article  PubMed  PubMed Central  Google Scholar 

  • Khaw, K. T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 116, 2694–2701.

    Article  CAS  PubMed  Google Scholar 

  • Kiguradze, T., Temps, W. H., Yarnold, P. R., Cashy, J., Brannigan, R. E., Nardone, B., Micali, G., West, D. P., & Belknap, S. M. (2017). Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. Peer J, 5, e3020.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim, S., Kwon, H., Park, J. H., Cho, B., Kim, D., Oh, S. W., Lee, C. M., & Choi, H. C. (2012). A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology, 12, 69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Salonen, R., Rauramaa, R., & Salonen, J. T. (2003). Sex hormones, inflammation and the metabolic syndrome: A population-based study. European Journal of Endocrinology, 149, 601–608.

    Article  CAS  PubMed  Google Scholar 

  • Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T. P., Valkonen, V. P., Salonen, R., & Salonen, J. T. (2004). Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27, 1036–1041.

    Article  CAS  PubMed  Google Scholar 

  • Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Valkonen, V. P., & Salonen, J. T. (2005). The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. The Journal of Clinical Endocrinology and Metabolism, 90, 712–719.

    Article  CAS  PubMed  Google Scholar 

  • Lage, M. J., Barber, B. L., & Markus, R. A. (2007). Association between androgen deprivation therapy and incidence of diabetes among males with prostate cancer. Urology, 70, 1104–1108.

    Article  CAS  PubMed  Google Scholar 

  • Lee, M. J., Pramyothin, P., Karastergiou, K., & Fried, S. K. (2014). Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochimica et Biophysica Acta (BBA), 1842, 473–481.

    Google Scholar 

  • Liu, L., Zhao, S., Li, F., Li, E., Kang, R., Luo, L., Luo, J., Wan, S., & Zhao, Z. (2016). Effect of 5α-reductase inhibitors on sexual function: A meta-analysis and systematic review of randomized controlled trials. The Journal of Sexual Medicine, 13, 1297–1310.

    Article  PubMed  Google Scholar 

  • Livingstone, D. E., Grassick, S. L., Currie, G. L., Walker, B. R., & Andrew, R. (2009). Dysregulation of glucocorticoid metabolism in murine obesity: Comparable effects of leptin resistance and deficiency. The Journal of Endocrinology, 201, 211–218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Livingstone, D. E., Di Rollo, E. M., Yang, C., Codrington, L. E., Mathews, J. A., Kara, M., Hughes, K. A., Kenyon, C. J., Walker, B. R., & Andrew, R. (2014). Relative adrenal insufficiency in mice deficient in 5α-reductase 1. The Journal of Endocrinology, 222, 257–266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Livingstone, D. E., Barat, P., Di Rollo, E. M., Rees, G. A., Weldin, B. A., Rog-Zielinska, E. A., MacFarlane, D. P., Walker, B. R., & Andrew, R. (2015). 5α-reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes, 64, 447–458.

    Article  CAS  PubMed  Google Scholar 

  • Livingstone, D. E., Di Rollo, E. M., Mak, T. C., Sooy, K., Walker, B. R., & Andrew, R. (2017). Metabolic dysfunction in female mice with disruption of 5α-reductase 1. The Journal of Endocrinology, 232, 29–36.

    Article  CAS  PubMed  Google Scholar 

  • Lugg, J. A., Rajfer, J., & Gonzalez-Cadavid, N. F. (1995). Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology, 136, 1495–1501.

    Article  CAS  PubMed  Google Scholar 

  • Maggi, M., Wu, F. C., Jones, T. H., Jackson, G., Behre, H. M., Hackett, G., Martin-Morales, A., Balercia, G., Dobs, A. S., Arver, S. T., Maggio, M., Cunningham, G. R., Isidori, A. M., Quinton, R., Wheaton, O. A., Siami, F. S., Rosen, R. C., & RHYME Investigators. (2016). Testosterone treatment is not associated with increased risk of adverse cardiovascular events: Results from the Registry of Hypogonadism in Men (RHYME). International Journal of Clinical Practice, 70, 843–852.

    Article  CAS  PubMed  Google Scholar 

  • Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004). The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 89, 3313–3318.

    Article  CAS  PubMed  Google Scholar 

  • Malkin, C. J., Jones, T. H., & Channer, K. S. (2007). The effect of testosterone on insulin sensitivity in men with heart failure. European Journal of Heart Failure, 9, 44–50.

    Article  CAS  PubMed  Google Scholar 

  • Maneschi, E., Morelli, A., Filippi, S., Cellai, I., Comeglio, P., Mazzanti, B., Mello, T., Calcagno, A., Sarchielli, E., Vignozzi, L., Saad, F., Vettor, R., Vannelli, G. B., & Maggi, M. (2012). Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. The Journal of Endocrinology, 215, 347–362.

    Article  CAS  PubMed  Google Scholar 

  • Mantzoros, C. S., Georgiadis, E. I., & Trichopoulos, D. (1995). Contribution of dihydrotestosterone to male sexual behavior. BMJ, 310, 1289–1291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Manzo, J., Cruz, M. R., Hernandez, M. E., Pacheco, P., & Sachs, B. D. (1999). Regulation of noncontact erection in rats by gonadal steroids. Hormones and Behavior, 35, 264–270.

    Article  CAS  PubMed  Google Scholar 

  • Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., Macairan, M. L., & Nelson, P. S. (2006). Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial. Journal of the American Medical Association, 296, 2351–2361.

    Article  CAS  PubMed  Google Scholar 

  • Mather, K. J., Kim, C., Christophi, C. A., Aroda, V. R., Knowler, W. C., Edelstein, S. E., Florez, J. C., Labrie, F., Kahn, S. E., Goldberg, R. B., & Barrett-Connor, E. (2015). Diabetes prevention program. steroid sex hormones, sex hormone-binding globulin, and diabetes incidence in the diabetes prevention program. The Journal of Clinical Endocrinology and Metabolism, 100, 3778–3786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mauvais-Jarvis, F. (2016). Androgen-deprivation therapy and pancreatic β-cell dysfunction in men. Journal of Diabetes and its Complications, 30, 389–390.

    Article  PubMed  Google Scholar 

  • Mauvais-Jarvis, F., Kulkarni, R. N., & Kahn, C. R. (2002). Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clinical Endocrinology, 57, 1–9.

    Article  CAS  PubMed  Google Scholar 

  • McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Pappas, F., & Stoner, E. (1992). Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. The Journal of Clinical Endocrinology and Metabolism, 74, 505–508.

    CAS  PubMed  Google Scholar 

  • McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., & Waldstreicher, J. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. The New England Journal of Medicine, 338, 557–563.

    Article  CAS  PubMed  Google Scholar 

  • Melcangi, R. C., Caruso, D., Abbiati, F., Giatti, S., Calabrese, D., Piazza, F., & Cavaletti, G. (2013). Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. The Journal of Sexual Medicine, 10, 2598–2603.

    Article  CAS  PubMed  Google Scholar 

  • Melcangi, R. C., Santi, D., Spezzano, R., Grimoldi, M., Tabacchi, T., Fusco, M. L., Diviccaro, S., Giatti, S., Carrà, G., Caruso, D., Simoni, M., & Cavaletti, G. (2017). Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. The Journal of Steroid Biochemistry and Molecular Biology, 171, 229–235.

    Article  CAS  PubMed  Google Scholar 

  • Mella, J. M., Perret, M. C., Manzotti, M., Catalano, H. N., & Guyatt, G. (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Archives of Dermatology, 146, 1141–1150.

    Article  PubMed  Google Scholar 

  • Mohamedali, H. Z., Breunis, H., Timilshina, N., & Alibhai, S. M. (2011). Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Canadian Urological Association Journal, 5, 28–32.

    Article  PubMed  PubMed Central  Google Scholar 

  • Morgentaler, A., Miner, M. M., Caliber, M., Guay, A. T., Khera, M., & Traish, A. M. (2015a). Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clinic Proceedings, 90, 224–251.

    Article  CAS  PubMed  Google Scholar 

  • Morgentaler, A., Zitzmann, M., Traish, A. M., & Fox, A. (2015b). International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. The Aging Male, 18, 205–206.

    Article  CAS  PubMed  Google Scholar 

  • Morgentaler, A., Zitzmann, M., Traish, A. M., Fox, A. W., Jones, T. H., Maggi, M., Arver, S., Aversa, A., Chan, J. C., Dobs, A. S., Hackett, G. I., Hellstrom, W. J., Lim, P., Lunenfeld, B., Mskhalaya, G., Schulman, C. C., & Torres, L. O. (2016). Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Mayo Clinic Proceedings, 91, 881–896.

    Article  PubMed  Google Scholar 

  • Muller, M., Grobbee, D. E., den Tonkelaar, I., Lamberts, S. W., & van der Schouw, Y. T. (2005). Endogenous sex hormones and metabolic syndrome in aging men. The Journal of Clinical Endocrinology and Metabolism, 90, 2618–2623.

    Article  CAS  PubMed  Google Scholar 

  • Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: The HIM study. International Journal of Clinical Practice, 60, 762–769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Na, Y., Ye, Z., Zhang, S., & Chinese Dutasteride Phase III Trial (ARIA108898) Study Group. (2012). Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: A randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clinical Drug Investigation, 32, 29–39.

    Article  CAS  Google Scholar 

  • Narayanan, R., Mohler, M. L., Bohl, C. E., Miller, D. D., & Dalton, J. T. (2008). Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 6, e010.

    PubMed  PubMed Central  Google Scholar 

  • Nasiri, M., Nikolaou, N., Parajes, S., Krone, N. P., Valsamakis, G., Mastorakos, G., Hughes, B., Taylor, A., Bujalska, I. J., Gathercole, L. L., & Tomlinson, J. W. (2015). 5α-reductase type 2 regulates glucocorticoid action and metabolic phenotype in human hepatocytes. Endocrinology, 156, 2863–2871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Navarro, G., Allard, C., Xu, W., & Mauvais-Jarvis, F. (2015). The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring), 23, 713–719.

    Article  CAS  Google Scholar 

  • Navarro, G., Xu, W., Jacobson, D. A., Wicksteed, B., Allard, C., Zhang, G., De Gendt, K., Kim, S. H., Wu, H., Zhang, H., Verhoeven, G., Katzenellenbogen, J. A., & Mauvais-Jarvis, F. (2016). Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metabolism, 23, 837–851.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology and Metabolism, 84, 3459–3462.

    Article  CAS  PubMed  Google Scholar 

  • Nguyen, P. L., Alibhai, S. M., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015a). Adverse effects of androgen deprivation therapy and strategies to mitigate them. European Urology, 67, 825–836.

    Article  CAS  PubMed  Google Scholar 

  • Nguyen, C. P., Hirsch, M. S., Moeny, D., Kaul, S., Mohamoud, M., & Joffe, H. V. (2015b). Testosterone and “Age-Related Hypogonadism” – FDA concerns. The New England Journal of Medicine, 373, 689–691.

    Article  PubMed  Google Scholar 

  • Nishiyama, T., Ishizaki, F., Anraku, T., Shimura, H., & Takahashi, K. (2005). The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 90, 657–660.

    Article  CAS  PubMed  Google Scholar 

  • Oh, J. Y., Barrett-Connor, E., Wedick, N. M., Wingard, D. L., & Rancho Bernardo Study. (2002). Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care, 25, 55–60.

    Article  CAS  PubMed  Google Scholar 

  • Oka, R., Utsumi, T., Endo, T., Yano, M., Kamijima, S., Kamiya, N., Shirai, K., & Suzuki, H. (2016). Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: A prospective study of initial 6-month follow-up. International Journal of Clinical Oncology, 21, 389–396.

    Article  CAS  PubMed  Google Scholar 

  • Osuna, J. A., Gomez-Perez, R., Arata-Bellabarba, G., & Villaroel, V. (2006). Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Archives of Andrology, 52, 355–361.

    Article  CAS  PubMed  Google Scholar 

  • Oztekin, C. V., Gur, S., Abdulkadir, N. A., Lokman, U., Akdemir, A. O., Cetinkaya, M., & Hellstrom, W. J. (2012). Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. The Journal of Sexual Medicine, 9, 1773–1781.

    Article  CAS  PubMed  Google Scholar 

  • Page, S. T., Herbst, K. L., Amory, J. K., Coviello, A. D., Anawalt, B. D., Matsumoto, A. M., & Bremner, W. J. (2005a). Testosterone administration suppresses adiponectin levels in men. Journal of Andrology, 26, 85–92.

    CAS  PubMed  Google Scholar 

  • Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005b). Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. The Journal of Clinical Endocrinology and Metabolism, 90, 1502–1510.

    Article  CAS  PubMed  Google Scholar 

  • Pagotto, U., Gambineri, A., Pelusi, C., Genghini, S., Cacciari, M., Otto, B., Castaneda, T., Tschop, M., & Pasquali, R. (2003). Testosterone replacement therapy restores normal ghrelin in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 88, 4139–4143.

    Article  CAS  PubMed  Google Scholar 

  • Park, T., & Choi, J. Y. (2014). Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): A systematic review and meta-analysis. World Journal of Urology, 32, 1093–1105.

    Article  CAS  PubMed  Google Scholar 

  • Pasquali, R., Casimirri, F., Cantobelli, S., Melchionda, N., Morselli Labate, A. M., Fabbri, R., Capelli, M., & Bortoluzzi, L. (1991). Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism, 40, 101–104.

    Article  CAS  PubMed  Google Scholar 

  • Pasquali, R., Macor, C., Vicennati, V., Novo, F., De lasio, R., Mesini, P., Boschi, S., Casimirri, F., & Vettor, R. (1997). Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism, 46, 526–529.

    Article  CAS  PubMed  Google Scholar 

  • Permpongkosol, S., Khupulsup, K., Leelaphiwat, S., Pavavattananusorn, S., Thongpradit, S., & Petchthong, T. (2016). Effects of 8-year treatment of long- acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism. The Journal of Sexual Medicine, 13, 1199–1211.

    Article  PubMed  Google Scholar 

  • Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology, Biology, Physics, 61, 1285–1290.

    Article  CAS  PubMed  Google Scholar 

  • Pinsky, M. R., Gur, S., Tracey, A. J., Harbin, A., & Hellstrom, W. J. (2011). The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. The Journal of Sexual Medicine, 8, 3066–3074.

    Article  CAS  PubMed  Google Scholar 

  • Pitteloud, N., Hardin, M., Dwyer, A. A., Valassi, E., Yialamas, M., Elahi, D., & Hayes, F. J. (2005a). Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. The Journal of Clinical Endocrinology and Metabolism, 90, 2636–2641.

    Article  CAS  PubMed  Google Scholar 

  • Pitteloud, N., Mootha, V. K., Dwyer, A. A., Hardin, M., Lee, H., Eriksson, K. F., Tripathy, D., Yialamas, M., Groop, L., Elahi, D., & Hayes, F. J. (2005b). Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care, 28, 1636–1642.

    Article  CAS  PubMed  Google Scholar 

  • Pitteloud, N., Dwyer, A. A., DeCruz, S., Lee, H., Boepple, P. A., Crowley, W. F., Jr., & Hayes, F. J. (2008). Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: Evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. The Journal of Clinical Endocrinology and Metabolism, 93, 784–791.

    Article  CAS  PubMed  Google Scholar 

  • Polonsky, K. S. (1995). Lilly lecture 1994. The beta-cell in diabetes: From molecular genetics to clinical research. Diabetes, 44, 705–717.

    Article  CAS  PubMed  Google Scholar 

  • Prentki, M., & Nolan, C. J. (2006). Islet beta cell failure in type 2 diabetes. The Journal of Clinical Investigation., 116, 1802–1812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Purnell, J. Q., Kahn, S. E., Samuels, M. H., Brandon, D., Loriaux, D. L., & Brunzell, J. D. (2009). Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: Effect of weight loss. American Journal of Physiology. Endocrinology and Metabolism, 296, E351–E357.

    Article  CAS  PubMed  Google Scholar 

  • Rao, P. M., Kelly, D. M., & Jones, T. H. (2013). Testosterone and insulin resistance in the metabolic syndrome and type 2 diabetes. Nature Reviews Endocrinology, 9, 479–493.

    Article  CAS  PubMed  Google Scholar 

  • Resnick, S. M., Matsumoto, A. M., Stephens-Shields, A. J., Ellenberg, S. S., Gill, T. M., Shumaker, S. A., Pleasants, D. D., Barrett-Connor, E., Bhasin, S., Cauley, J. A., Cella, D., Crandall, J. P., Cunningham, G. R., Ensrud, K. E., Farrar, J. T., Lewis, C. E., Molitch, M. E., Pahor, M., Swerdloff, R. S., Cifelli, D., Anton, S., Basaria, S., Diem, S. J., Wang, C., Hou, X., & Snyder, P. J. (2017). Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. Journal of the American Medical Association, 317, 717–727.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rhoden, E. L., Ribeiro, E. P., Riedner, C. E., Teloken, C., & Souto, C. A. (2005a). Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU International, 95, 615–617.

    Article  CAS  PubMed  Google Scholar 

  • Rhoden, E. L., Ribeiro, E. P., Teloken, C., & Souto, C. A. (2005b). Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU International, 96, 867–870.

    Article  CAS  PubMed  Google Scholar 

  • Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., & ARIA3001 ARIA3002 and ARIA3003 Study Investigators. (2002). Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60, 434–441.

    Article  PubMed  Google Scholar 

  • Roehrborn, C. G., Siami, P., Barkin, J., Damiao, R., Major-Walker, K., Morrill, B., & Montorsi, F. (2008). The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. The Journal of Urology, 179, 616–621.

    Article  CAS  PubMed  Google Scholar 

  • Roehrborn, C. G., Perez, I. O., Roos, E. P., Calomfirescu, N., Brotherton, B., Wang, F., Palacios, J. M., Vasylyev, A., & Manyak, M. J. (2015). Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart™) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU International, 116, 450–459.

    Article  CAS  PubMed  Google Scholar 

  • Rovira-Llopis, S., Bañuls, C., de Marañon, A. M., Diaz-Morales, N., Jover, A., Garzon, S., Rocha, M., Victor, V. M., & Hernandez-Mijares, A. (2017a). Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Radical Biology & Medicine, 108, 155–162.

    Article  CAS  Google Scholar 

  • Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Hernandez-Mijares, A., Rocha, M., & Victor, V. M. (2017b). Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. Redox Biology, 11, 637–645.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roy, C. N., Snyder, P. J., Stephens-Shields, A. J., Artz, A. S., Bhasin, S., Cohen, H. J., Farrar, J. T., Gill, T. M., Zeldow, B., Cella, D., Barrett-Connor, E., Cauley, J. A., Crandall, J. P., Cunningham, G. R., Ensrud, K. E., Lewis, C. E., Matsumoto, A. M., Molitch, M. E., Pahor, M., Swerdloff, R. S., Cifelli, D., Hou, X., Resnick, S. M., Walston, J. D., Anton, S., Basaria, S., Diem, S. J., Wang, C., Schrier, S. L., & Ellenberg, S. S. (2017). Association of testosterone levels with anemia in older men: A controlled clinical trial. JAMA Internal Medicine, 177, 480–490.

    Article  PubMed  Google Scholar 

  • Rubinow, K. B., Snyder, C. N., Amory, J. K., Hoofnagle, A. N., & Page, S. T. (2012). Acute testosterone deprivation reduces insulin sensitivity in men. Clinical Endocrinology, 76, 281–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saad, F. (2015). Androgen deprivation therapy in prostate cancer: Looking beyond prostate-specific antigen and testosterone levels. European Urology, 67, 837–838.

    Article  PubMed  Google Scholar 

  • Saad, F., & Gooren, L. (2009). The role of testosterone in the metabolic syndrome: A review. The Journal of Steroid Biochemistry and Molecular Biology, 114, 40–43.

    Article  CAS  PubMed  Google Scholar 

  • Saad, F., & Gooren, L. J. (2011). The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Journal of Obesity, 2011, 1–10. pii: 471584.

    Google Scholar 

  • Saad, F., Gooren, L., Haider, A., & Yassin, A. (2008a). Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia, 40, 44–48.

    Article  CAS  PubMed  Google Scholar 

  • Saad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008b). A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. Journal of Andrology, 29, 102–105.

    Article  CAS  PubMed  Google Scholar 

  • Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011). Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology, 165, 675–685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saad, F., Aversa, A., Isidori, A. M., & Gooren, L. J. (2012). Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: A review. Current Diabetes Reviews, 8, 131–143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saad, F., Haider, A., Doros, G., & Traish, A. (2013). Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring), 21, 1975–1981.

    Article  CAS  Google Scholar 

  • Saad, F., Yassin, A., Doros, G., & Haider, A. (2016). Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: Observational data from two registry studies. International Journal of Obesity, 40, 162–170.

    Article  CAS  PubMed  Google Scholar 

  • Saad, F., Röhrig, G., von Haehling, S., & Traish, A. (2017). Testosterone deficiency and testosterone treatment in older men. Gerontology, 63, 144–156.

    Article  CAS  PubMed  Google Scholar 

  • Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., Litwin, M. S., & Urologic Diseases in America Project. (2007). Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer, 110, 1493–1500.

    Article  CAS  PubMed  Google Scholar 

  • Saksena, S. K., Lau, I. F., & Chang, M. C. (1976). The inhibition of the conversion of testosterone into 5alpha-dihydrotestosterone in the reproductive organs of the male rat. Steroids, 27, 751–757.

    Article  CAS  PubMed  Google Scholar 

  • Saylor, P. J., & Smith, M. R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. The Journal of Urology, 181, 1998–2006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Selvin, E., Feinleib, M., Zhang, L., Rohrmann, S., Rifai, N., Nelson, W., Dobs, A., Basaria, S., Golden, S., & Platz, E. (2007). Androgens and diabetes in men. Diabetes Care, 30, 234–238.

    Article  CAS  PubMed  Google Scholar 

  • Seo, S. I., Kim, S. W., & Paick, J. S. (1999). The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian Journal of Andrology, 1, 169–174.

    CAS  PubMed  Google Scholar 

  • Shahani, S., Braga-Basaria, M., & Basaria, S. (2008). Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. The Journal of Clinical Endocrinology and Metabolism, 93, 2042–2049.

    Article  CAS  PubMed  Google Scholar 

  • Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Ambrose, J. A., & Barua, R. S. (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European Heart Journal, 36, 2706–2715.

    Article  PubMed  Google Scholar 

  • Sharma, R., Oni, O. A., Gupta, K., Sharma, M., Sharma, R., Singh, V., Parashara, D., Kamalakar, S., Dawn, B., Chen, G., Ambrose, J. A., & Barua, R. S. (2017). Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. Journal of American Heart Association, 6(5). pii: e004880. https://doi.org/10.1161/JAHA.116.004880.

  • Shastri, B. R., & Yaturu, S. (2011). Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. Prostate Cancer, 2011, 391576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006). Low serum testosterone and mortality in male veterans. Archives of Internal Medicine, 166, 1660–1665.

    Article  CAS  PubMed  Google Scholar 

  • Simon, D., Charles, M. A., Nahoul, K., Orssaud, G., Kremski, J., Hully, V., Joubert, E., Papoz, L., & Eschwege, E. (1997). Assocation between plasma total testosterone and cardiovascular risk factors in healthy adult men: The telecom study. The Journal of Clinical Endocrinology and Metabolism, 82, 682–685.

    CAS  PubMed  Google Scholar 

  • Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003). Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology, 144, 5081–5088.

    Article  CAS  PubMed  Google Scholar 

  • Singh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N. F., & Bhasin, S. (2006). Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: Nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology, 147, 141–154.

    Article  CAS  PubMed  Google Scholar 

  • Singh, S. K., Goyal, R., & Pratyush, D. D. (2011). Is hypoandrogenemia a component of metabolic syndrome in males? Experimental and Clinical Endocrinology & Diabetes, 119, 30–35.

    Article  CAS  Google Scholar 

  • Skeldon, S. C., Macdonald, E. M., Law, M. R., Huang, A., Paterson, J. M., Mamdani, M. M., & Juurlink, D. (2017). The cardiovascular safety of dutasteride. The Journal of Urology, 197, 1309–1314.

    Article  CAS  PubMed  Google Scholar 

  • Smith, M. R. (2004). Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology, 63, 742–745.

    Article  PubMed  Google Scholar 

  • Smith, M. R. (2007a). Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clinical Cancer Research, 13, 241–245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith, M. R. (2007b). Androgen deprivation therapy for prostate cancer: New concepts and concerns. Current Opinion in Endocrinology, Diabetes, and Obesity, 14, 247–254.

    Article  PubMed  PubMed Central  Google Scholar 

  • Smith, M. R. (2008). Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Current Urology Reports, 9, 197–202.

    Article  PubMed  PubMed Central  Google Scholar 

  • Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 86, 4261–4267.

    Article  CAS  PubMed  Google Scholar 

  • Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of Clinical Endocrinology and Metabolism., 87, 599–603.

    Article  CAS  PubMed  Google Scholar 

  • Smith, M. R., Lee, H., & Nathan, D. M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 91, 1305–1308.

    Article  CAS  PubMed  Google Scholar 

  • Smith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., Philipson, L. H., Stoffers, D. A., Seeley, R. J., & D’Alessio, D. A. (2014). The role of beta cell glucagon-like peptide- 1 signaling in glucose regulation and response to diabetes drugs. Cell Metabolism, 19, 1050–1057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Snyder, P. J., Peachey, H., Hannoush, P., Berlin, J. A., Loh, L., Holmes, J. H., Dlewati, A., Staley, J., Santanna, J., Kapoor, S. C., Attie, M. F., Haddad, J. G., Jr., & Strom, B. L. (1999a). Effect of testosterone treatment on bone mineral density in men over 65 years of age. The Journal of Clinical Endocrinology and Metabolism, 84, 1966–1972.

    CAS  PubMed  Google Scholar 

  • Snyder, P. J., Peachey, H., Hannoush, P., Berlin, J. A., Loh, L., Lenrow, D. A., Holmes, J. H., Dlewati, A., Santanna, J., Rosen, C. J., & Strom, B. L. (1999b). Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. The Journal of Clinical Endocrinology and Metabolism, 84, 2647–2653.

    CAS  PubMed  Google Scholar 

  • Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., Ensrud, K. E., Lewis, C. E., Farrar, J. T., Cella, D., Rosen, R. C., Pahor, M., Crandall, J. P., Molitch, M. E., Cifelli, D., Dougar, D., Fluharty, L., Resnick, S. M., Storer, T. W., Anton, S., Basaria, S., Diem, S. J., Hou, X., Mohler, E. R., 3rd, Parsons, J. K., Wenger, N. K., Zeldow, B., Landis, J. R., Ellenberg, S. S., & Testosterone Trials Investigators. (2016). Effects of testosterone treatment in older men. The New England Journal of Medicine, 374, 611–624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., Bhasin, S., Cunningham, G. R., Gill, T. M., Matsumoto, A. M., Swerdloff, R. S., Basaria, S., Diem, S. J., Wang, C., Hou, X., Cifelli, D., Dougar, D., Zeldow, B., Bauer, D. C., & Keaveny, T. M. (2017). Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Internal Medicine, 177, 471–479.

    Article  PubMed  Google Scholar 

  • Soni, K. G., Lehner, R., Metalnikov, P., O'Donnell, P., Semache, M., Gao, W., Ashman, K., Pshezhetsky, A. V., & Mitchell, G. A. (2004). Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase. The Journal of Biological Chemistry, 279, 40683–40689.

    Article  CAS  PubMed  Google Scholar 

  • Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O’Connell, M. D., Adams, J. E., Oldham, J. A., & Wu, F. C. (2010). Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Endocrinology and Metabolism, 95, 639–650.

    Article  CAS  PubMed  Google Scholar 

  • Steinbrook, R. (2006). Facing the diabetes epidemic—Mandatory reporting of glycosylated hemoglobin values in New York City. The New England Journal of Medicine, 354, 545–548.

    Article  CAS  PubMed  Google Scholar 

  • Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000). Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care, 23, 490–494.

    Article  CAS  PubMed  Google Scholar 

  • Svartberg, J., von Mühlen, D., Sundsfjord, J., & Jorde, R. (2004). Waist circumference and testosterone levels in community dwelling men. The Tromsø study. European Journal of Epidemiology, 19, 657–663.

    Article  CAS  PubMed  Google Scholar 

  • Tan, R. S., Cook, K. R., & Reilly, W. G. (2015). Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. International Journal of Endocrinology, 2015, 970750.

    PubMed  PubMed Central  Google Scholar 

  • Thigpen, A. E., & Russell, D. W. (1992). Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. The Journal of Biological Chemistry, 267, 8577–8583.

    Google Scholar 

  • Tomlinson, J. W., Finney, J., Gay, C., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008). Impaired glucose tolerance and insulin resistance are associated with increased adipose 11 -hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5 -reductase activity. Diabetes, 57, 2652–2660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Traish, A. M. (2012). 5α-reductases in human physiology: An unfolding story. Endocrine Practice, 18, 965–975.

    Article  PubMed  Google Scholar 

  • Traish, A. M. (2014a). Adverse health effects of testosterone deficiency (TD) in men. Steroids, 88, 106–116.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M. (2014b). Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids, 88, 117–126.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M. (2014c). Testosterone and weight loss: The evidence. Current Opinion in Endocrinology, Diabetes, and Obesity, 21, 313–322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Traish, A. M. (2016a). Testosterone therapy in men with testosterone deficiency: Are the benefits and cardiovascular risks real or imagined? American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 311, R566–R573.

    Article  PubMed  Google Scholar 

  • Traish, A. (2016b). Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? Investigative and Clinical Urology, 57, 384–400.

    Article  PubMed  PubMed Central  Google Scholar 

  • Traish, A. M., & Galoosian, A. (2013). Androgens modulate endothelial function and endothelial progenitor cells in erectile physiology. Korean Journal of Urology, 54, 721–731.

    Article  PubMed  PubMed Central  Google Scholar 

  • Traish, A. M., & Guay, A. T. (2006). Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. The Journal of Sexual Medicine, 3, 382–404.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., & Zitzmann, M. (2015). The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Reviews in Endocrine & Metabolic Disorders, 16, 249–268.

    Article  CAS  Google Scholar 

  • Traish, A. M., Park, K., Dhir, V., Kim, N. N., Moreland, R. B., & Goldstein, I. (1999). Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology, 140, 1861–1868.

    Google Scholar 

  • Traish, A. M., Saad, F., & Guay, A. (2009a). The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. Journal of Andrology, 30, 23–32.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., Saad, F., Feeley, R. J., & Guay, A. (2009b). The dark side of testosterone deficiency: III. Cardiovascular disease. Journal of Andrology, 30, 477–494.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009c). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology, 30, 10–22.

    Google Scholar 

  • Traish, A. M., Abdou, R., & Kypreos, K. E. (2009d). Androgen deficiency and atherosclerosis: The lipid link. Vascular Pharmacology, 51, 303–313.

    Google Scholar 

  • Traish, A. M., Miner, M. M., Morgentaler, A., & Zitzmann, M. (2011a). Testosterone deficiency. The American Journal of Medicine, 124, 578–587.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., Abdallah, B., & Yu, G. (2011b). Androgen deficiency and mitochondrial dysfunction: Implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. Hormone Molecular Biology and Clinical Investigation, 8, 431–444.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011c). Adverse side effects of 5α-reductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and depression in a subset of patients. The Journal of Sexual Medicine., 8, 872–884.

    Article  CAS  PubMed  Google Scholar 

  • Traish, A. M., Haider, A., Doros, G., & Saad, F. (2014a). Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: An observational, long-term registry study. International Journal of Clinical Practice, 68, 314–329.

    Google Scholar 

  • Traish, A. M., Mulgaonkar, A., & Giordano, N. (2014b). The dark side of 5α-reductase inhibitors’ therapy: Sexual dysfunction, high Gleason grade prostate cancer and depression. Korean Journal of Urology, 55, 367–379.

    Google Scholar 

  • Traish, A. M., Guay, A. T., & Zitzmann, M. (2014c). 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: A medical hypothesis. Hormone Molecular Biology and Clinical Investigation, 20, 73–80.

    Google Scholar 

  • Traish, A. M., Haider, K. S., Doros, G., & Haider, A. (2015a). Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Hormone Molecular Biology and Clinical Investigation, 23, 85–96.

    Google Scholar 

  • Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. M., & Zitzmann, M. (2015b). Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Reviews in Endocrine & Metabolic Disorders, 16, 177–198.

    Google Scholar 

  • Traish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017a). Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. Journal of Cardiovascular Pharmacology and Therapeutics. 1074248417691136. https://doi.org/10.1177/1074248417691136.

  • Traish, A., Haider, K. S., Doros, G., & Haider, A. (2017b). Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Hormone Molecular Biology and Clinical Investigations. pii: /j/hmbci.ahead-of-print/hmbci-2017-0015/hmbci-2017-0015.xml. https://doi.org/10.1515/hmbci-2017-0015.

  • Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., & Boyko, E. J. (2004). Association of bioavailable, free, and total testosterone with insulin resistance: Influence of sex hormone-binding globulin and body fat. Diabetes Care, 27, 861–868.

    Article  CAS  PubMed  Google Scholar 

  • Tsai, H. K., D’Amico, A. V., Sadetsky, N., Chen, M. H., & Carroll, P. R. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute, 99, 1516–2154.

    Article  PubMed  Google Scholar 

  • Tsai, H. T., Keating, N. L., Van Den Eeden, S. K., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Smith, M. R., & Potosky, A. L. (2015). Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. The Journal of Urology, 193, 1956–1962.

    Article  CAS  PubMed  Google Scholar 

  • U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK. Prospective Diabetes Study Group. Diabetes, 44(11), 1249–1258. (1995).

    Google Scholar 

  • Upreti, R., Hughes, K. A., Livingstone, D. E., Gray, C. D., Minns, F. C., Macfarlane, D. P., Marshall, I., Stewart, L. H., Walker, B. R., & Andrew, R. (2014). 5α-reductase type 1 modulates insulin sensitivity in men. The Journal of Clinical Endocrinology and Metabolism, 99, E1397–E1406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • US Food and Drug Administration. (n.d.). Citizen petition denial response from FDA CDER to public citizen. Regulations. Gov website. http://www.regulations.gov/#!documentDetail; D.FDA-2014-P-0258-0003. Published July 16, 2014. Accessed 31 Aug 2014. http://www.citizen.org/documents/2184_FDA%20Denial%20of%20Petition_July%2016,%202014.pdf. Accessed 28 Apr 2016.

  • Usui, T., Kajita, K., Kajita, T., Mori, I., Hanamoto, T., Ikeda, T., Okada, H., Taguchi, K., Kitada, Y., Morita, H., Sasaki, T., Kitamura, T., Sato, T., Kojima, I., & Ishizuka, T. (2014). Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. FEBS Letters, 588, 1935–1941.

    Article  CAS  PubMed  Google Scholar 

  • Vandenput, L., Mellstrom, D., Lorentzon, M., Swanson, C., Karlsson, M. K., Brandberg, J., Lonn, L., Orwoll, E., Smith, U., Labrie, F., Ljunggren, O., Tivesten, A., & Ohlsson, C. (2007). Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. The Journal of Clinical Endocrinology and Metabolism, 92, 4130–4137.

    Article  CAS  PubMed  Google Scholar 

  • Vigen, R., O’Donnell, C. I., Barón, A. E., Grunwald, G. K., Maddox, T. M., Bradley, S. M., Barqawi, A., Woning, G., Wierman, M. E., Plomondon, M. E., Rumsfeld, J. S., & Ho, P. M. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310, 1829–1836. Erratum in: JAMA. 2014; 311:967.

    Article  CAS  PubMed  Google Scholar 

  • Vignozzi, L., Morelli, A., Corona, G., Sebastianelli, A., Serni, S., Gacci, M., Adorini, L., & Maggi, M. (2012). Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations. Hormone Molecular Biology and Clinical Investigation, 11, 329–337.

    Article  CAS  PubMed  Google Scholar 

  • Vikan, T., Schirmer, H., Njølstad, I., & Svartberg, J. (2010). Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European Journal of Endocrinology, 162, 747–754.

    Article  CAS  PubMed  Google Scholar 

  • Völzke, H., Aumann, N., Krebs, A., Nauck, M., Steveling, A., Lerch, M. M., Rosskopf, D., & Wallaschofski, H. (2010). Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. International Journal of Andrology, 33, 45–53.

    Article  CAS  PubMed  Google Scholar 

  • Walker, B. R., Stewart, P. M., Shackleton, C. H., Padfield, P. L., & Edwards, C. R. (1993). Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenases in essential hypertension. Clinical Endocrinology, 39, 221–227.

    Article  CAS  PubMed  Google Scholar 

  • Wallis, C. J., Lo, K., Lee, Y., Krakowsky, Y., Garbens, A., Satkunasivam, R., Herschorn, S., Kodama, R. T., Cheung, P., Narod, S. A., & Nam, R. K. (2016). Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. The Lancet Diabetes and Endocrinology, 4, 498–506.

    Article  CAS  PubMed  Google Scholar 

  • Wang, C., Swerdloff, R. S., Iranmanesh, A., Dobs, A., Snyder, P. J., Cunningham, G., Matsumoto, A. M., Weber, T., Berman, N., & Testosterone Gel Study Group. (2000). Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 85, 2839–2853.

    CAS  PubMed  Google Scholar 

  • Wang, C., Swerdloff, R. S., Iranmanesh, A., Dobs, A., Snyder, P. J., Cunningham, G., Matsumoto, A. M., Weber, T., & Berman, N. (2001). Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clinical Endocrinology, 54, 739–750.

    Article  PubMed  Google Scholar 

  • Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004). Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 89, 2085–2098.

    Article  CAS  PubMed  Google Scholar 

  • Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J. J., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., & Wu, F. C. (2008). Investigation, treatment and monitoring of late onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. European Journal of Endocrinology, 159, 507–514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang, C., Jackson, G., Jones, T. H., Matsumoto, A. M., Nehra, A., Perelman, M. A., Swerdloff, R. S., Traish, A., Zitzmann, M., & Cunningham, G. (2011). Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care, 34, 1669–1675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang, F., Yang, J., Sun, J., Dong, Y., Zhao, H., Shi, H., & Fu, L. (2015). Testosterone replacement attenuates mitochondrial damage in a rat model of myocardial infarction. The Journal of Endocrinology, 225, 101–111.

    Article  CAS  PubMed  Google Scholar 

  • Welk, B., McArthur, E., Ordon, M., Anderson, K. K., Hayward, J., & Dixon, S. (2017). Association of suicidality and depression with 5α-reductase Inhibitors. JAMA Internal Medicine, 177, 683–691.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wessells, H., Roy, J., Bannow, J., Grayhack, J., Matsumoto, A. M., Tenover, L., Herlihy, R., Fitch, W., Labasky, R., Auerbach, S., Parra, R., Rajfer, J., Culbertson, J., Lee, M., Bach, M. A., Waldstreicher, J., & PLESS Study Group. (2003). Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology, 61, 579–584.

    Article  PubMed  Google Scholar 

  • Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999). The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. The Journal of Clinical Investigation, 104, 787–794.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu, F. C., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., Huhtaniemi, I. T., Kula, K., Punab, M., Boonen, S., Vanderschueren, D., & European Male Aging Study Group. (2008). Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. The Journal of Clinical Endocrinology and Metabolism, 93, 2737–2745.

    Article  CAS  PubMed  Google Scholar 

  • Wu, F. C., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O’Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., Giwercman, A., Han, T. S., Kula, K., Lea, M. E. J., Pendleton, N., Punab, M., Boonen, S., Vanderschueren, D., Labrie, F., Huhtaniemi, I., & EMAS Group. (2010). Identification of late-onset hpogonadism in middle-aged and elderly men. The New England Journal of Medicine, 363, 123–135.

    Article  CAS  PubMed  Google Scholar 

  • Xu, Z. R., Hu, L., Cheng, L. F., Qian, Y., & Yang, Y. M. (2010). Dihydrotestosterone protects human vascular endothelial cells from H2O2-induced apoptosis through inhibition of caspase-3, caspase-9 and p38 MAPK. European Journal of Pharmacology, 643, 254–259.

    Article  CAS  PubMed  Google Scholar 

  • Xu, L., Freeman, G., Cowling, B. J., & Schooling, C. M. (2013). Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine, 18(11), 108.

    Article  CAS  Google Scholar 

  • Xu, W., Niu, T., Xu, B., Navarro, G., Schipma, M. J., & Mauvais-Jarvis, F. (2017). Androgen receptor-deficient islet β-cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse. Journal of Diabetes and its Complications, 31, 787–795.

    Article  PubMed  Google Scholar 

  • Yannucci, J., Manola, J., Garnick, M. B., Bhat, G., & Bubley, G. J. (2006). The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. The Journal of Urology, 176, 520–525.

    Article  PubMed  Google Scholar 

  • Yeap, B. B., Chubb, S. A., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., & Norman, P. E. (2009). Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: The Health In Men Study. European Journal of Endocrinology, 161, 591–598.

    Article  CAS  PubMed  Google Scholar 

  • Yeap, B. B., Araujo, A. B., & Wittert, G. A. (2012). Do low testosterone levels contribute to ill-health during male ageing? Critical Reviews in Clinical Laboratory Sciences, 49, 168–182.

    Article  CAS  PubMed  Google Scholar 

  • Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007). Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism, 92, 4254–4259.

    Article  CAS  PubMed  Google Scholar 

  • Yu, G., & Traish, A. M. (2011). Induced testosterone deficiency: From clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetes. Hormone Molecular Biology and Clinical Investigation, 8, 425–430.

    Article  CAS  PubMed  Google Scholar 

  • Zhang, H., Liu, Y., Wang, L., Li, Z., Zhang, H., Wu, J., Rahman, N., Guo, Y., Li, D., Li, N., Huhtaniemi, I., Tsang, S. Y., Gao, G. F., & Li, X. (2013a). Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. Journal of Lipid Research, 54, 345–357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang, M. G., Wang, X. J., Shen, Z. J., & Gao, P. J. (2013b). Long-term oral administration of 5alpha-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology, 82, 743.

    PubMed  Google Scholar 

  • Zhang, H., Shi, L., Ren, G. Q., Sun, W. W., Wang, Y. B., Chen, Y. K., Yin, J. N., & Wan, B. (2016a). Dihydrotestosterone modulates endothelial progenitor cell function via RhoA/ROCK pathway. American Journal of Translational Research, 8, 4300–4309.

    PubMed  PubMed Central  Google Scholar 

  • Zhang, L., Cai, Y., Wei, S., Ling, Y., Zhu, L., Li, D., & Cai, Z. (2016b). Testosterone deficiency induces changes of the transcriptomes of visceral adipose tissue in miniature pigs fed a high-fat and high-cholesterol diet. International Journal Molecular Science, 17(12). pii: E2125.

    Google Scholar 

  • Zitzmann, M., & Nieschlag, E. (2007). Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 92, 3844–3853.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Boston University School of Medicine, Boston, MA, USA

    Abdulmaged M. Traish

Authors
  1. Abdulmaged M. Traish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdulmaged M. Traish .

Editor information

Editors and Affiliations

  1. Department of Medicine, Section of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, Louisiana, USA

    Franck Mauvais-Jarvis

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Traish, A.M. (2017). Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. In: Mauvais-Jarvis, F. (eds) Sex and Gender Factors Affecting Metabolic Homeostasis, Diabetes and Obesity. Advances in Experimental Medicine and Biology, vol 1043. Springer, Cham. https://doi.org/10.1007/978-3-319-70178-3_22

Download citation

Publish with us

Policies and ethics

Search

Navigation